Anti-PD-1 for pretreated advanced anal carcinoma: which patients will benefit?
- PMID: 35114168
- DOI: 10.1016/S2468-1253(22)00002-4
Anti-PD-1 for pretreated advanced anal carcinoma: which patients will benefit?
Conflict of interest statement
I report personal fees from Bristol Myers Squibb and Incyte (consultancy, lectures), I received financial support for a congress registration (in France) from Merck Sharp & Dohme, and I am co-investigator of studies sponsored by Bristol Myers Squibb and Incyte.
Comment on
-
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.Lancet Gastroenterol Hepatol. 2022 May;7(5):446-454. doi: 10.1016/S2468-1253(21)00382-4. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35114169 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical